Inovio Pharmaceuticals had announced yesterday that its dMAB was successful in providing 100% protection against a lethal dose of chicungunya virus. This is particularly important, because the vaccine used consisted of pure DNA that codes for the protein coat of the chicungunya AND A DNA sequence that codes for the antibody against the chicungunya viral coat protein. The DNA that codes for the antibody caused antibody to show up in two days, while the DNA that coded for the viral protein coat caused the antibodies to show up in two weeks.
The dMAB technology (injectuion of DNA that codes for a Monoclonal antibody) was thus validated. The Company has about 30 different dMABS against infections and cancers.
Wednesday, March 23, 2016
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment